Veritas Intercontinental

The mission of Veritas Int. is to fulfill the promise of the human genome, empowering people to maximize the quality and length of life for themselves and their families. As the first company to introduce whole genome sequencing and interpretation to consumers and their physicians, we lead by relentlessly pushing the boundaries of science and technology while driving down the cost of the genome. Originally founded in 2014 by leaders in genomics from Harvard Medical School , Veritas Intercontinental was born in 2018 to deliver the promise of Whole Genome Sequencing outside United States. We have been recognized twice by MIT Technology Review as one of the 50 Smartest Companies in 2016 and 2017, by Fast Company as one of the world’s most innovative health companies in 2018, and by CNBC as one of the Disruptor 50 Companies in 2018.

Veritas Intercontinental headquartered in Europe, operates in the Biotechnology, Life Science, Genetics sector. The company focuses on Biotechnology and has secured $615.0M in funding across 24 round(s). With a team of 11-50 employees, Veritas Intercontinental is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Veritas Intercontinental, raised $5.6M. Discover more about their projects, partnerships, and impact on our platform.